EYPT today
$0.32-$0.04 (-10.40%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $0.44
Key levels
Resistance$2.21
Resistance$0.42
Latest news & SEC filings
EarningsEyePoint Pharmaceuticals holds Q3 2026 earnings call
EarningsEyePoint Pharmaceuticals Posts Q3 2026 Results
EarningsEyePoint Pharmaceuticals posts wider quarterly loss, revenue tops view
SEC FilingEyePoint, Inc. filed a report on a major company event (Form 8-K)
All EYPT news →About EyePoint
EyePoint is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. Its pipeline includes DURAVYU, an investigational sustained-release intravitreal therapy for wet age-related macular degeneration and diabetic macular edema, as well as other product candidates for retinal conditions. The company also markets YUTIQ and DEXYCU for certain ocular conditions. It operates primarily in the United States and collaborates with partners such as Ocumension Therapeutics and ANI Pharmaceuticals.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Technology
EyePoint, Inc. (EYPT)
What Is the Price Target for EYPT?
SEPT Low Target
$1.00
SEPT Mid Target
$1.00
SEPT High Target
$1.00
Analyst Consensus
$1.00
Is EYPT a Buy or Sell Right Now?
Thesis
- •Revenue growing -27.5% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EYPT.
Start Free Trial →Is EYPT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1395.31
12
Moat Score
NONE
2/9
Piotroski Score
-5.4
Altman Z-Score
What Is Smart Money Doing with EYPT?
Insider Signal
NEUTRAL
1 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Elston George | officer | Sale | 5,000 | - | Aug 20, 2026 |
| Elston George | officer | Sale | 64,953 | - | Aug 20, 2026 |
| Elston George | officer | Buy | 7,500 | - | May 25, 2026 |
| Elston George | officer | Sale | 3,627 | $47K | May 25, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →EYPT Growth Story
Revenue YoY
-27.5%
3yr Revenue CAGR
-8.8%
EPS Growth YoY
-36.64%
FCF Growth YoY
-86.8%
Revenue Trend
DECLINING
Dark Pool Trades for EYPT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for EYPT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:23:18 | $0.33 | 6,191 | $$2K | BUY |
| 23:00:45 | $0.33 | 1,817 | $$606 | SELL |
| 22:25:18 | $0.33 | 1,933 | $$645 | SELL |
| 22:21:48 | $0.33 | 3,867 | $$1K | SELL |
| 21:44:11 | $0.33 | 3,306 | $$1K | SELL |
5 dark pool trades shown · $$6K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for EyePoint, Inc. (EYPT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EYPT — frequently asked questions
What is EYPT stock price today?
EyePoint, Inc. (EYPT) is at $0.32, down 10.40% (-$0.04) at the Nov 12, 2026 close.
Why is EYPT stock moving today?
Latest EYPT news — Nov 12, 2026: EyePoint Pharmaceuticals holds Q3 2026 earnings call · Nov 12, 2026: EyePoint Pharmaceuticals Posts Q3 2026 Results
Why did EYPT stock move on Oct 20, 2026?
EyePoint shares fell 2.73% to close at $0.41, trading between a low of $0.41 and a high of $0.48 on heavy volume of 47,197,727. The decline followed a wave of negative analyst actions: Laidlaw & Co.
What is the EYPT price target?
The average analyst price target for EYPT is $1.00, ranging from $1 to $1, based on 1 analysts. Latest: RBC Capital maintains on Oct 20, 2026.
What do analysts rate EYPT?
Analyst ratings for EYPT: 1 Buy, 15 Hold, 2 Sell — consensus Hold.
Did EYPT beat earnings?
EYPT last reported on Nov 4, 2026: EPS -$0.91 vs -$0.93 expected — a beat of 2.2%.
Does EYPT pay a dividend?
EYPT does not currently pay a dividend.
What are EYPT support and resistance levels?
Resistance: $0.42, $2.21, $2.65.
What are insiders doing with EYPT?
Insider activity: NEUTRAL, 1 buys and 3 sells in the last 90 days.
What is the latest news on EYPT?
Nov 12, 2026: EyePoint Pharmaceuticals holds Q3 2026 earnings call · Nov 12, 2026: EyePoint Pharmaceuticals Posts Q3 2026 Results · Nov 12, 2026: EyePoint Pharmaceuticals posts wider quarterly loss, revenue tops view